 | • レポートコード：MRC2Q12-19435 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、膣抗感染症のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 膣抗感染症のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 膣抗感染症の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 膣抗感染症のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの膣抗感染症の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の膣抗感染症の売上および2028年までの予測に焦点を当てています。 膣抗感染症のグローバル主要企業には、Pfizer Inc、Mylan N.V、Novartis AG、Hikma Pharmaceuticals plc、Aurobindo Pharma、AbbVie Inc、Melinta Therapeutics, Inc、Bristol-Myers Squibb Company、GSK plc、Bayer AG、Lupin、Perrigo Company plcなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 膣抗感染症市場は、タイプとアプリケーションによって区分されます。世界の膣抗感染症市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 内服、軟膏 【アプリケーション別セグメント】 細菌性膣炎、トリコモナス膣炎、カンジダ性膣炎 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 膣抗感染症製品概要 - タイプ別市場（内服、軟膏） - アプリケーション別市場（細菌性膣炎、トリコモナス膣炎、カンジダ性膣炎） - 調査の目的 ・エグゼクティブサマリー - 世界の膣抗感染症販売量予測2017-2028 - 世界の膣抗感染症売上予測2017-2028 - 膣抗感染症の地域別販売量 - 膣抗感染症の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別膣抗感染症販売量 - 主要メーカー別膣抗感染症売上 - 主要メーカー別膣抗感染症価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（内服、軟膏） - 膣抗感染症のタイプ別販売量 - 膣抗感染症のタイプ別売上 - 膣抗感染症のタイプ別価格 ・アプリケーション別市場規模（細菌性膣炎、トリコモナス膣炎、カンジダ性膣炎） - 膣抗感染症のアプリケーション別販売量 - 膣抗感染症のアプリケーション別売上 - 膣抗感染症のアプリケーション別価格 ・北米市場 - 北米の膣抗感染症市場規模（タイプ別、アプリケーション別） - 主要国別の膣抗感染症市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの膣抗感染症市場規模（タイプ別、アプリケーション別） - 主要国別の膣抗感染症市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の膣抗感染症市場規模（タイプ別、アプリケーション別） - 主要国別の膣抗感染症市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の膣抗感染症市場規模（タイプ別、アプリケーション別） - 主要国別の膣抗感染症市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの膣抗感染症市場規模（タイプ別、アプリケーション別） - 主要国別の膣抗感染症市場規模（トルコ、サウジアラビア） ・企業情報 Pfizer Inc、Mylan N.V、Novartis AG、Hikma Pharmaceuticals plc、Aurobindo Pharma、AbbVie Inc、Melinta Therapeutics, Inc、Bristol-Myers Squibb Company、GSK plc、Bayer AG、Lupin、Perrigo Company plc ・産業チェーン及び販売チャネル分析 - 膣抗感染症の産業チェーン分析 - 膣抗感染症の原材料 - 膣抗感染症の生産プロセス - 膣抗感染症の販売及びマーケティング - 膣抗感染症の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 膣抗感染症の産業動向 - 膣抗感染症のマーケットドライバー - 膣抗感染症の課題 - 膣抗感染症の阻害要因 ・主な調査結果 |
Vaginal anti-infectives are the type of agents that are used for the killing or supressing the infection of vagina caused by numerous bacteria, virus, fungi or micro-organism. These bacteria and others invade the host by means of its replication or releasing several toxins into the host. “Yeast” infections, tyrichomoniasis vaginitis, bacterial vaginosis, chlamydia vaginitis, and viral vaginitis are the major forms of vaginitis. About one third women all over the world experience indications of vaginitis at some point in their lifetime. Women are highly prone to vaginitis during the reproductive age; a change in the balance of bacteria and yeast present in vagina can lead to vaginitis.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Vaginal Anti Infectives is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Vaginal Anti Infectives is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Vaginal Anti Infectives is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Vaginal Anti Infectives include Pfizer Inc, Mylan N.V, Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc, Melinta Therapeutics, Inc, Bristol-Myers Squibb Company and GSK plc, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Vaginal Anti Infectives manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Vaginal Anti Infectives market. Further, it explains the major drivers and regional dynamics of the global Vaginal Anti Infectives market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Pfizer Inc
Mylan N.V
Novartis AG
Hikma Pharmaceuticals plc
Aurobindo Pharma
AbbVie Inc
Melinta Therapeutics, Inc
Bristol-Myers Squibb Company
GSK plc
Bayer AG
Lupin
Perrigo Company plc
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Vaginal Anti Infectives Segment by Type
Oral
Ointment
Vaginal Anti Infectives Segment by Application
Bacterial Vaginitis
Trichomonal Vaginitis
Candida Vaginitis
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Vaginal Anti Infectives market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Vaginal Anti Infectives, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Vaginal Anti Infectives, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Vaginal Anti Infectives, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Vaginal Anti Infectives sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Vaginal Anti Infectives market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Vaginal Anti Infectives sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer Inc, Mylan N.V, Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc, Melinta Therapeutics, Inc, Bristol-Myers Squibb Company and GSK plc, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Vaginal Anti Infectives in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Vaginal Anti Infectives manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaginal Anti Infectives sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Vaginal Anti Infectives Product Introduction
1.2 Market by Type
1.2.1 Global Vaginal Anti Infectives Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Ointment
1.3 Market by Application
1.3.1 Global Vaginal Anti Infectives Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Bacterial Vaginitis
1.3.3 Trichomonal Vaginitis
1.3.4 Candida Vaginitis
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Vaginal Anti Infectives Sales Estimates and Forecasts 2017-2028
2.2 Global Vaginal Anti Infectives Revenue Estimates and Forecasts 2017-2028
2.3 Global Vaginal Anti Infectives Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Vaginal Anti Infectives Sales by Region
2.4.1 Global Vaginal Anti Infectives Sales by Region (2017-2022)
2.4.2 Global Sales Vaginal Anti Infectives by Region (2023-2028)
2.5 Global Vaginal Anti Infectives Revenue by Region
2.5.1 Global Vaginal Anti Infectives Revenue by Region (2017-2022)
2.5.2 Global Vaginal Anti Infectives Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Vaginal Anti Infectives Sales by Manufacturers
3.1.1 Global Top Vaginal Anti Infectives Manufacturers by Sales (2017-2022)
3.1.2 Global Vaginal Anti Infectives Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Vaginal Anti Infectives in 2021
3.2 Global Vaginal Anti Infectives Revenue by Manufacturers
3.2.1 Global Vaginal Anti Infectives Revenue by Manufacturers (2017-2022)
3.2.2 Global Vaginal Anti Infectives Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Vaginal Anti Infectives Revenue in 2021
3.3 Global Vaginal Anti Infectives Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Vaginal Anti Infectives Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Vaginal Anti Infectives Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Vaginal Anti Infectives Sales by Type
4.1.1 Global Vaginal Anti Infectives Historical Sales by Type (2017-2022)
4.1.2 Global Vaginal Anti Infectives Forecasted Sales by Type (2023-2028)
4.1.3 Global Vaginal Anti Infectives Sales Market Share by Type (2017-2028)
4.2 Global Vaginal Anti Infectives Revenue by Type
4.2.1 Global Vaginal Anti Infectives Historical Revenue by Type (2017-2022)
4.2.2 Global Vaginal Anti Infectives Forecasted Revenue by Type (2023-2028)
4.2.3 Global Vaginal Anti Infectives Revenue Market Share by Type (2017-2028)
4.3 Global Vaginal Anti Infectives Price by Type
4.3.1 Global Vaginal Anti Infectives Price by Type (2017-2022)
4.3.2 Global Vaginal Anti Infectives Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Vaginal Anti Infectives Sales by Application
5.1.1 Global Vaginal Anti Infectives Historical Sales by Application (2017-2022)
5.1.2 Global Vaginal Anti Infectives Forecasted Sales by Application (2023-2028)
5.1.3 Global Vaginal Anti Infectives Sales Market Share by Application (2017-2028)
5.2 Global Vaginal Anti Infectives Revenue by Application
5.2.1 Global Vaginal Anti Infectives Historical Revenue by Application (2017-2022)
5.2.2 Global Vaginal Anti Infectives Forecasted Revenue by Application (2023-2028)
5.2.3 Global Vaginal Anti Infectives Revenue Market Share by Application (2017-2028)
5.3 Global Vaginal Anti Infectives Price by Application
5.3.1 Global Vaginal Anti Infectives Price by Application (2017-2022)
5.3.2 Global Vaginal Anti Infectives Price Forecast by Application (2023-2028)
6 North America
6.1 North America Vaginal Anti Infectives Market Size by Type
6.1.1 North America Vaginal Anti Infectives Sales by Type (2017-2028)
6.1.2 North America Vaginal Anti Infectives Revenue by Type (2017-2028)
6.2 North America Vaginal Anti Infectives Market Size by Application
6.2.1 North America Vaginal Anti Infectives Sales by Application (2017-2028)
6.2.2 North America Vaginal Anti Infectives Revenue by Application (2017-2028)
6.3 North America Vaginal Anti Infectives Market Size by Country
6.3.1 North America Vaginal Anti Infectives Sales by Country (2017-2028)
6.3.2 North America Vaginal Anti Infectives Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Vaginal Anti Infectives Market Size by Type
7.1.1 Europe Vaginal Anti Infectives Sales by Type (2017-2028)
7.1.2 Europe Vaginal Anti Infectives Revenue by Type (2017-2028)
7.2 Europe Vaginal Anti Infectives Market Size by Application
7.2.1 Europe Vaginal Anti Infectives Sales by Application (2017-2028)
7.2.2 Europe Vaginal Anti Infectives Revenue by Application (2017-2028)
7.3 Europe Vaginal Anti Infectives Market Size by Country
7.3.1 Europe Vaginal Anti Infectives Sales by Country (2017-2028)
7.3.2 Europe Vaginal Anti Infectives Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Vaginal Anti Infectives Market Size by Type
8.1.1 Asia Pacific Vaginal Anti Infectives Sales by Type (2017-2028)
8.1.2 Asia Pacific Vaginal Anti Infectives Revenue by Type (2017-2028)
8.2 Asia Pacific Vaginal Anti Infectives Market Size by Application
8.2.1 Asia Pacific Vaginal Anti Infectives Sales by Application (2017-2028)
8.2.2 Asia Pacific Vaginal Anti Infectives Revenue by Application (2017-2028)
8.3 Asia Pacific Vaginal Anti Infectives Market Size by Region
8.3.1 Asia Pacific Vaginal Anti Infectives Sales by Region (2017-2028)
8.3.2 Asia Pacific Vaginal Anti Infectives Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Vaginal Anti Infectives Market Size by Type
9.1.1 Latin America Vaginal Anti Infectives Sales by Type (2017-2028)
9.1.2 Latin America Vaginal Anti Infectives Revenue by Type (2017-2028)
9.2 Latin America Vaginal Anti Infectives Market Size by Application
9.2.1 Latin America Vaginal Anti Infectives Sales by Application (2017-2028)
9.2.2 Latin America Vaginal Anti Infectives Revenue by Application (2017-2028)
9.3 Latin America Vaginal Anti Infectives Market Size by Country
9.3.1 Latin America Vaginal Anti Infectives Sales by Country (2017-2028)
9.3.2 Latin America Vaginal Anti Infectives Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Vaginal Anti Infectives Market Size by Type
10.1.1 Middle East and Africa Vaginal Anti Infectives Sales by Type (2017-2028)
10.1.2 Middle East and Africa Vaginal Anti Infectives Revenue by Type (2017-2028)
10.2 Middle East and Africa Vaginal Anti Infectives Market Size by Application
10.2.1 Middle East and Africa Vaginal Anti Infectives Sales by Application (2017-2028)
10.2.2 Middle East and Africa Vaginal Anti Infectives Revenue by Application (2017-2028)
10.3 Middle East and Africa Vaginal Anti Infectives Market Size by Country
10.3.1 Middle East and Africa Vaginal Anti Infectives Sales by Country (2017-2028)
10.3.2 Middle East and Africa Vaginal Anti Infectives Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Pfizer Inc
11.1.1 Pfizer Inc Corporation Information
11.1.2 Pfizer Inc Overview
11.1.3 Pfizer Inc Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Pfizer Inc Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Inc Recent Developments
11.2 Mylan N.V
11.2.1 Mylan N.V Corporation Information
11.2.2 Mylan N.V Overview
11.2.3 Mylan N.V Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Mylan N.V Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Mylan N.V Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Corporation Information
11.3.2 Novartis AG Overview
11.3.3 Novartis AG Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Novartis AG Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novartis AG Recent Developments
11.4 Hikma Pharmaceuticals plc
11.4.1 Hikma Pharmaceuticals plc Corporation Information
11.4.2 Hikma Pharmaceuticals plc Overview
11.4.3 Hikma Pharmaceuticals plc Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Hikma Pharmaceuticals plc Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Hikma Pharmaceuticals plc Recent Developments
11.5 Aurobindo Pharma
11.5.1 Aurobindo Pharma Corporation Information
11.5.2 Aurobindo Pharma Overview
11.5.3 Aurobindo Pharma Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Aurobindo Pharma Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Aurobindo Pharma Recent Developments
11.6 AbbVie Inc
11.6.1 AbbVie Inc Corporation Information
11.6.2 AbbVie Inc Overview
11.6.3 AbbVie Inc Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 AbbVie Inc Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 AbbVie Inc Recent Developments
11.7 Melinta Therapeutics, Inc
11.7.1 Melinta Therapeutics, Inc Corporation Information
11.7.2 Melinta Therapeutics, Inc Overview
11.7.3 Melinta Therapeutics, Inc Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Melinta Therapeutics, Inc Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Melinta Therapeutics, Inc Recent Developments
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Corporation Information
11.8.2 Bristol-Myers Squibb Company Overview
11.8.3 Bristol-Myers Squibb Company Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Bristol-Myers Squibb Company Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bristol-Myers Squibb Company Recent Developments
11.9 GSK plc
11.9.1 GSK plc Corporation Information
11.9.2 GSK plc Overview
11.9.3 GSK plc Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 GSK plc Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 GSK plc Recent Developments
11.10 Bayer AG
11.10.1 Bayer AG Corporation Information
11.10.2 Bayer AG Overview
11.10.3 Bayer AG Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Bayer AG Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Bayer AG Recent Developments
11.11 Lupin
11.11.1 Lupin Corporation Information
11.11.2 Lupin Overview
11.11.3 Lupin Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Lupin Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Lupin Recent Developments
11.12 Perrigo Company plc
11.12.1 Perrigo Company plc Corporation Information
11.12.2 Perrigo Company plc Overview
11.12.3 Perrigo Company plc Vaginal Anti Infectives Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Perrigo Company plc Vaginal Anti Infectives Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Perrigo Company plc Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Vaginal Anti Infectives Industry Chain Analysis
12.2 Vaginal Anti Infectives Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaginal Anti Infectives Production Mode & Process
12.4 Vaginal Anti Infectives Sales and Marketing
12.4.1 Vaginal Anti Infectives Sales Channels
12.4.2 Vaginal Anti Infectives Distributors
12.5 Vaginal Anti Infectives Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Vaginal Anti Infectives Industry Trends
13.2 Vaginal Anti Infectives Market Drivers
13.3 Vaginal Anti Infectives Market Challenges
13.4 Vaginal Anti Infectives Market Restraints
14 Key Findings in The Global Vaginal Anti Infectives Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer